Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2018

View Archived Issues

Microenvironment trouble underlies chemo brain

Antiviral response damages kidney in bacterial sepsis

New pyrrolidine sulfonamides as TRPV4 antagonists

DNA-encoded monoclonal antibody targeting PCSK9 reduces LDL cholesterol in mice

Preliminary results presented from first-in-human study of ACTR-707 in combination with rituximab

Vecabrutinib shows preliminary evidence of activity in advanced B-cell malignancies

Bristol-Myers Squibb presents phase Ib/II data for ulocuplumab in multiple myeloma

Higher toxicity and lower adherence for alternative palbociclib dosing schedule in breast cancer

BAT-8003, a novel anti-Trop-2 ADC with promising activity in TNBC mouse models

OncoSec reports updated tumor response data for KEYNOTE-695 study

Lilly and AC Immune enter agreement to research and develop tau aggregation inhibitors

Rodin Therapeutics initiates phase I study of RDN-929

GARDP to screen libraries from Eisai and Takeda for new antibiotics

OBI Pharma opens phase III trial of adagloxad simolenin and OBI-821 for high-risk early-stage TNBC

Virginia Tech collaborates with NIH to study ML-351 for chronic pain

Mutation in orexin receptor is associated with panic disorder development and response to therapy

Targeting alpha-synuclein can mitigate stroke damage

Czech Academy of Sciences institutes patent PGE2 production inhibitors

Cancer Research Technology discovers BCL-6 inhibitors

Ono Pharmaceutical identifies new prostanoid EP4 receptor antagonists

Chinese researchers divulge RORC antagonists

Protagonist begins phase I study of PN-10943 for inflammatory bowel disease

Seliforant shown not to affect vigilance, cognitive performance during motion stimulus

Phase I primary endpoint met in phase I/II study of NC-6300

Rhythm begins phase III trial of setmelanotide in Bardet-Biedl syndrome and Alstrom syndrome

Aptevo initiates phase I/Ib study of APVO-436 for AML and MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....